BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
3.38
-0.15 (-4.25%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.34 - 3.57
52 week 2.53 - 9.91
Open 3.50
Vol / Avg. 0.00/1.23M
Mkt cap 173.09M
P/E     -
Div/yield     -
EPS -0.72
Shares 53.47M
Beta 2.16
Inst. own 87%
Jul 15, 2016
BioDelivery Sciences International Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
Jun 14, 2016
BioDelivery Sciences International Inc at William Blair Growth Stock Conference Add to calendar
Jun 7, 2016
BioDelivery Sciences International Inc at Jefferies Healthcare Conference Add to calendar
May 23, 2016
Dar Es Salaam Investment Bank PJSC Annual Shareholders Meeting (Estimated) Add to calendar
May 10, 2016
Q1 2016 BioDelivery Sciences International Inc Earnings Release Add to calendar
Mar 14, 2016
BioDelivery Sciences International Inc at ROTH Conference
Mar 10, 2016
Q4 2015 BioDelivery Sciences International Inc Earnings Call
Mar 10, 2016
Q4 2015 BioDelivery Sciences International Inc Earnings Release
Mar 8, 2016
BioDelivery Sciences International Inc at Cowen Health Care Conference
Feb 25, 2016
BioDelivery Sciences International Inc Analyst and Investor Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 31.58% -78.11%
Operating margin 34.01% -72.94%
EBITD margin - -70.25%
Return on average assets 46.58% -39.32%
Return on average equity 158.77% -87.52%
Employees 40 -
CDP Score - -

Address

4131 Parklake Avenue, Suite 225
RALEIGH, NC 27612
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Niraj Vasisht Senior Vice President, Chief Technology Officer
Bio & Compensation  - Reuters
Albert J. Medwar Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Stephana E. Patton Ph.D., J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Sarah DeRossett Vice President - Clinical Research and Medical Affairs
Bio & Compensation  - Reuters
Joseph Lockhart Vice President - Manufacturing and Supply Chain
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 54
Bio & Compensation  - Reuters